Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions

NCT ID: NCT05783908

Last Updated: 2025-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-16

Study Completion Date

2025-09-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The patients eligible for the study are those treated by radiotherapy on Linac MRI for a mobile cancerous lesion (pancreas, liver, kidneys, adrenals, lung, adenopathy above or below the diaphragm ...).

After signing the consent form, each patient will be randomized to one of two treatment arms:

* Standard arm : Radiotherapy treatment with Linac MRI without non-magnetic shielding
* Experimental arm : radiotherapy treatment with Linac MRI with non-magnetic screen The aim is to evaluate the effect of using a non-magnetic screen visible to the patient in the bunker during radiotherapy sessions delivered by Linac MRI on decreasing the ratio between the actual treatment time and the treatment time predicted by the machine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The patients eligible for the study are those treated by radiotherapy on Linac MRI for a mobile cancerous lesion (pancreas, liver, kidneys, adrenals, lung, adenopathy above or below the diaphragm ...).

After signing the consent form, each patient will be randomized to one of two treatment arms:

* Standard arm : Radiotherapy treatment with Linac MRI without non-magnetic shielding
* Experimental arm : radiotherapy treatment with Linac MRI with non-magnetic screen

The aim is to compare the effect of the non-magnetic screen on the blocking of the patient's breathing versus the current procedure (the blocking of the breathing is informed by the staff)

The patients will each receive 5 sessions of radiotherapy on Linac MRI. 100 patients are expected to participate in this study

Before each session will be assessed for anxiety and stress. After each session will be evaluated patient satisfaction, pain intensity and respiratory effort.

The duration of the treatment and therefore of the follow-up of the patient in the study is 1 to 2 weeks

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient With Radiotherapy (Linac MRI) Mobile Cancerous Lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Without Non-magnetic screen

Radiotherapy treatment with Linac MRI without non-magnetic shielding

Group Type NO_INTERVENTION

No interventions assigned to this group

With non-magnetic screen

Radiotherapy treatment with Linac MRI with non-magnetic screen

Group Type EXPERIMENTAL

With non-magnetic screen

Intervention Type COMBINATION_PRODUCT

Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

With non-magnetic screen

Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is at least 18 years old
* Patient starting radiotherapy on Linac MRI for a mobile cancerous lesion most often in the pancreas, liver, kidneys, adrenals, lung, supra or subdiaphragmatic adenopathy
* Patient affiliated to the social security system

Exclusion Criteria

* Patient with lesions not detected by the device's tracking system
* Patient with visual disturbances
* Contraindications to treatment with Linac MRI (epileptic patients, pregnant or breastfeeding women, metallic prosthesis or pacemaker not compatible with MRI)
* Patients with cognitive disorders
* Persons deprived of liberty or under guardianship (including curatorship)
* Pregnant or nursing woman
* Refusal to participate in the study
Minimum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Georges Francois Leclerc

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Georges-François Leclerc

Dijon, Côte d'Or, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gilles TRUC, Doctor

Role: CONTACT

03 80 73 75 18 ext. +33

Sophie PARNALLAND, Project Manager

Role: CONTACT

03 45 34 80 77 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gilles TRUC, Dr

Role: primary

03 80 73 75 18 ext. +33

Sophie PARNALLAND, Project Manager

Role: backup

03 45 34 80 77 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A02774-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.